Merck has announced that the antagonist of the calcitonin gene-related peptide (CGRP) receptor telcagepant has met the primary end points in two Phase III trials to treat migraine, which is ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The compounds are oral small molecules based on three distinct mechanistic platforms: calcitonin gene-related peptide (CGRP) receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors.

No new safety signals emerged after concomitant atogepant plus ubrogepant in patients with atogepant-refractory episodic migraine.